X0303 4 2009-10-15 1 0000005187 WYETH WYE 0001113681 MASCOTTE JOHN P WYETH 5 GIRALDA FARMS MADISON NJ 07940 1 0 0 0 Common Stock 2009-10-15 4 D 0 4000 D 0 D Common Stock (Restricted Stock Trust) 2009-10-15 4 D 0 13564.4538 49.58 D 0 I Restricted Stock Trust Non-Employee Director Stock Option 56.5938 2009-10-15 4 D 0 3000 0.00 D Common Stock 3000 0 D Non-Employee Director Stock Option 56.525 2009-10-15 4 D 0 4000 0.00 D Common Stock 4000 0 D Non-Employee Director Stock Option 60.705 2009-10-15 4 D 0 4000 0.00 D Common Stock 4000 0 D Non-Employee Director Stock Option 41.05 2009-10-15 4 D 0 4000 8.53 D Common Stock 4000 0 D Non-Employee Director Stock Option 40.22 2009-10-15 4 D 0 4000 9.36 D Common Stock 4000 0 D Non-Employee Director Stock Option 43.57 2009-10-15 4 D 0 4000 6.01 D Common Stock 4000 0 D Non-Employee Director Stock Option 48.22 2009-10-15 4 D 0 3500 1.36 D Common Stock 3500 0 D Non-Employee Director Stock Option 56.00 2009-10-15 4 D 0 3500 0.00 D Common Stock 3500 0 D Phantom Stock Units (Retirement) 2009-10-15 4 D 0 18291.645 49.58 D Common Stock 18291.645 0 D Pursuant to the Agreement and Plan of Merger by and among Wyeth, Pfizer Inc. and Wagner Acquisition Corp. dated as of January 25, 2009 (as amended, the "Merger Agreement"), each of these shares was cancelled at the effective time of the merger and converted into the right to receive $33.00 in cash and 0.985 of a share of Pfizer Inc. common stock. Pursuant to the Merger Agreement, each of these shares was cancelled at the effective time of the merger in exchange for cash equal to the per share value of the merger consideration of $49.58. Pursuant to the Merger Agreement, each outstanding and unexercised option, whether vested or unvested, was cancelled at the effective time of the merger in exchange for cash equal to the product of (a) the number of shares underlying such option and (b) the excess, if any, of the per share value of the merger consideration of $49.58 over the per share exercise price of the option. Pursuant to the Merger Agreement, all phantom stock units, each of which represents the value of one actual share of common stock and has no exercise feature or expiration date, was cancelled at the effective time of the merger in exchange for cash equal to the product of (a) the number of shares underlying the phantom stock units and (b) the per share value of the merger consideration of $49.58. Tara J. Gabbai, Attorney-in-Fact for John P. Mascotte 2009-10-19